nsacpi
Expects Yuge Games
Fluvoxamine, a cheap and widely available pill used around the world to treat mental illness, is very likely to reduce the risk of being hospitalized with Covid-19, according to new peer reviewed research published in JAMA Network Open, opening up another possible treatment option for the disease using a medicine with a decades-long track record.
Based on an analysis of data from three different clinical trials, the researchers said there is a “high probability” fluvoxamine was associated with “at least a moderate reduction in Covid-19 hospitalizations.”
The trials, which enrolled a total of nearly 2,200 unvaccinated Covid-positive patients from the U.S., Brazil and Canada, evaluated how well 100mg of fluvoxamine taken twice a day reduced the risk of being hospitalized with the disease.
The analysis, coupled with the fact that fluvoxamine is “immediately available, safe and inexpensive” around the world, makes the drug a “reasonable option for high-risk outpatients” who don’t have access to other Covid treatments like antiviral drugs or monoclonal antibodies, the researchers said.
However, they stressed it is important clinical trials examining fluvoxamine continue to bolster the results, especially those studying lower doses of the drug and how effective it is in vaccinated individuals.
A similar and widely available antidepressant, fluoxetine, should also be studied for its potential to treat Covid-19, the researchers said.
https://www.forbes.com/sites/robert...25bf0ba5611ec83d53c7df7b55ccc&sh=4e59cc402b58
Based on an analysis of data from three different clinical trials, the researchers said there is a “high probability” fluvoxamine was associated with “at least a moderate reduction in Covid-19 hospitalizations.”
The trials, which enrolled a total of nearly 2,200 unvaccinated Covid-positive patients from the U.S., Brazil and Canada, evaluated how well 100mg of fluvoxamine taken twice a day reduced the risk of being hospitalized with the disease.
The analysis, coupled with the fact that fluvoxamine is “immediately available, safe and inexpensive” around the world, makes the drug a “reasonable option for high-risk outpatients” who don’t have access to other Covid treatments like antiviral drugs or monoclonal antibodies, the researchers said.
However, they stressed it is important clinical trials examining fluvoxamine continue to bolster the results, especially those studying lower doses of the drug and how effective it is in vaccinated individuals.
A similar and widely available antidepressant, fluoxetine, should also be studied for its potential to treat Covid-19, the researchers said.
https://www.forbes.com/sites/robert...25bf0ba5611ec83d53c7df7b55ccc&sh=4e59cc402b58